A Phase 1 Dose-Escalation Study of SLV-154 in Subjects with Metastatic Solid Tumors
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs SLV 154 (Primary)
- Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Head and neck cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Sarcoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors Solve Therapeutics
- 25 Jan 2025 New trial record